N-(3-(氯甲基)苯甲酰基)哌啶 | 148583-64-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3-(氯甲基)苯甲酰基)哌啶
• 英文名称: N-(3-(chloromethyl)benzoyl)piperidine
• 英文别名: 1(3-chloromethylbenzoyl)piperidine；1-[3-(Chloromethyl)benzoyl]piperidine；[3-(chloromethyl)phenyl]-piperidin-1-ylmethanone
• CAS: 148583-64-6
• 化学式: C₁₃H₁₆ClNO
• mdl: MFCD11053040
• 分子量: 237.729
• InChiKey: BXLNHFVIUOMFIA-UHFFFAOYSA-N

物化性质

• 沸点：
  396.8±25.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(3-(氯甲基)苯甲酰基)哌啶 在 劳森试剂 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 8.0h， 生成 {3-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-phenyl}-piperidin-1-yl-methanethione
  参考文献：
  名称：

  Orally Active Benzamide Antipsychotic Agents with Affinity for Dopamine D₂, Serotonin 5-HT_1A, and Adrenergic α₁ Receptors

  摘要：

  New antipsychotic drugs are needed because current therapy is ineffective for many schizophrenics and because treatment is often accompanied by extrapyramidal symptoms and dyskinesias. This paper describes the design, synthesis, and evaluation of a series of related (aminomethyl)benzamides in assays predictive of antipsychotic activity in humans. These compounds had notable affinity for dopamine D-2, serotonin 5-HT1A, and alpha(1)-adrenergic receptors. The arylpiperazine 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]piperidine (mazapertine, 6) was chosen because of its overall profile for evaluation in human clinical trials. The corresponding 4-arylpiperidine derivative 67 was also highly active indicating that the aniline nitrogen of 6 is not required for activity. Other particularly active structures include homopiperidine amide 14 and N-methylcyclohexylamide 31.

  DOI：

  10.1021/jm970164z
• 作为产物：
  描述：

  3-(氯甲基)苯甲酰氯 生成 N-(3-(氯甲基)苯甲酰基)哌啶
  参考文献：
  名称：

  4-arylpiperazines and 4-arylpiperidines

  摘要：

  本文披露了一种新型抗精神病药物，其一般式为I：##STR1##。

  公开号：

  US05569659A1

文献信息

• Tricyclic compounds having affinity for the 5-HT1A receptor
  申请人：Ortho Pharmaceutical Corporation

  公开号：US05512566A1

  公开（公告）日：1996-04-30

  Compounds represented by the general formula I: ##STR1## are disclosed as useful in treating diseases of the central nervous system.

  通式I: ##STR1## 所代表的化合物被披露为在治疗中枢神经系统疾病中有用。
• Antipsychotic substituted piperidine derivatives
  申请人：Akzo Nobel NV

  公开号：US06365604B1

  公开（公告）日：2002-04-02

  The present invention relates to certain novel substituted piperidine derivatives of formula (I) to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, particularly in the treatment of psychotic disorders.

  本发明涉及某些新颖的式(I)取代哌啶衍生物，涉及其制备方法，含有它们的药物配方以及它们在医学治疗中的应用，特别是在治疗精神病性障碍方面。
• [EN] NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES
  申请人：McNEILAB, INC.

  公开号：WO1993004684A1

  公开（公告）日：1993-03-18

  (EN) Compounds of the general formula (I) are disclosed as novel antipsychotic agents.(FR) Cette invention concerne des composés de formule (I) utiles comme nouveaux agents antipsychotiques.

  (I)式化合物被披露为新型抗精神病药物。(FR)该发明涉及公式（I）的化合物，作为新型抗精神病药物。
• Substituted piperidine derivatives
  申请人：——

  公开号：US20020087001A1

  公开（公告）日：2002-07-04

  The present invention relates to certain novel substituted piperidine derivatives, to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, particularly in the treatment of psychotic disorders.

  本发明涉及某些新颖的取代哌啶衍生物，以及制备它们的方法，含有它们的制药配方以及它们在医疗治疗中的使用，特别是在治疗精神疾病方面的应用。
• A New Arylpiperazine Antipsychotic with High D2/D3/5-HT1A/.alpha.1A-Adrenergic Affinity and a Low Potential for Extrapyramidal Effects
  作者：Allen B. Reitz、Debra J. Bennett、Paul S. Blum、Ellen E. Codd、Cynthia A. Maryanoff、Marta E. Ortegon、Michael J. Renzi、Malcolm K. Scott、Richard P. Shank、Jeffry L. Vaught

  DOI：10.1021/jm00034a003

  日期：1994.4